New anti-cancer drug extends life of melanoma victims

A new experimental drug developed by Bristol-Myers Squibb and Medarex extends the lives of patients with advanced melanoma, the deadliest form of skin cancer, researchers said.

The results paved the way for dealing with a form of cancer that has few treatment options. Melanoma cases have climbed faster than any other cancer type over the past 30 years, researchers said.

Nearly a quarter - 24 percent - of patients with advanced melanoma survived for an unusual two years after being administered intravenously with ipilimumab.

Forty-four to 46 percent of patients treated with ipilimumab were alive after one year of trials compared to 25 percent of patients treated with other methods, the study pointed out.

"Randomized clinical trials have repeatedly failed to demonstrate an improvement in overall survival in patients with advanced melanoma," said lead author Steven O'Day, who heads the melanoma program at The Angeles Clinic and Research Institute in southern California.

O'Day described the study findings as "an exciting advance, both for patients with advanced melanoma and for the field of cancer immunology."

He presented the study at the American Society of Clinical Oncology meeting this weekend in Chicago.

Lynn Schuchter, professor of medicine at Abramson Cancer Center at the University of Pennsylvania, said these findings were "really exciting" because ipilimumab and other new cancer drugs produced far fewer side effects than traditional chemotherapy.

"This drug takes the brake off and allows for further immunological response, and this is going to be the first time that a trial with patients with advanced melanoma shows a survival benefit," Schuchter said.

She noted that just six months ago, doctors really had no effective therapy for patients with stage 4 melanoma.

Ipilimumab belongs to a new class of drugs that activate the immune system's T cells, which then seek and destroy melanoma cells, instead of targeting the cancer cell itself like previous treatments.

In the clinical test, patients who took ipilimumab or were treated with a combination of the antibody and a peptide vaccine, also aimed at boosting the immune system, lived a median of 10 months, against 6.5 months for those administered a placebo or a peptide vaccine alone.

The Phase III clinical trial studied some 600 melanoma patients in several countries. Patients generally tolerated the treatment well, the researchers said.

Experts pointed out that given the success of the trials, the US Food and Drug Administration was expected to grant permission to market the medicine relatively quickly.

Ipilimumab was forecast to generate more than 400 million dollars in sales in the first several years following its approval.

Melanoma is one of the deadliest forms of cancer, and the number of people affected by it has been increasing for 30 years, according to the World Health Organization.

Skin cancer annually kills 66,000 people around the world, the WHO said, and 80 percent of these deaths are attributable to melanoma.

As many as 68,000 new cases of melanoma were diagnosed in the United States last year, and about 8,600 people died of the disease.

In France, 7,000 cases of melanoma are detected each year, and an average of 1,300 of them have a fatal outcome.

Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Chiropractic Assistant

    £16500 per annum: Recruitment Genius: A Chiropractic Assistant is needed in a ...

    Recruitment Genius: Digital Account Executive - Midlands

    £18000 - £26000 per annum: Recruitment Genius: They work with major vehicle ma...

    Recruitment Genius: Web Developer

    £28000 - £30000 per annum: Recruitment Genius: This company provides coaching ...

    Ashdown Group: Front-End UI Application Developer

    £30000 - £40000 per annum + Benefits: Ashdown Group: Front-End UI Application ...

    Day In a Page

    Where the spooks get their coffee fix: The busiest Starbucks in the US is also the most secretive

    The secret CIA Starbucks

    The coffee shop is deep inside the agency's forested Virginia compound
    Revealed: How the Establishment closed ranks over fallout from Loch Ness Monster 'sighting'

    How the Establishment closed ranks over fallout from Nessie 'sighting'

    The Natural History Museum's chief scientist was dismissed for declaring he had found the monster
    One million Britons using food banks, according to Trussell Trust

    One million Britons using food banks

    Huge surge in number of families dependent on emergency food aid
    Excavation at Italian cafe to fix rising damp unearths 2,500 years of history in 3,000 amazing objects

    2,500 years of history in 3,000 amazing objects

    Excavation at Italian cafe to fix rising damp unearths trove
    The Hubble Space Telescope's amazing journey, 25 years on

    The Hubble Space Telescope's amazing journey 25 years on

    The space telescope was seen as a costly flop on its first release
    Did Conservative peer Lord Ashcroft quit the House of Lords to become a non-dom?

    Did Lord Ashcroft quit the House of Lords to become a non-dom?

    A document seen by The Independent shows that a week after he resigned from the Lords he sold 350,000 shares in an American company - netting him $11.2m
    Apple's ethnic emojis are being used to make racist comments on social media

    Ethnic emojis used in racist comments

    They were intended to promote harmony, but have achieved the opposite
    Sir Kenneth Branagh interview: 'My bones are in the theatre'

    Sir Kenneth Branagh: 'My bones are in the theatre'

    The actor-turned-director’s new company will stage five plays from October – including works by Shakespeare and John Osborne
    The sloth is now the face (and furry body) of three big advertising campaigns

    The sloth is the face of three ad campaigns

    Priya Elan discovers why slow and sleepy wins the race for brands in need of a new image
    How to run a restaurant: As two newbies discovered, there's more to it than good food

    How to run a restaurant

    As two newbies discovered, there's more to it than good food
    Record Store Day: Remembering an era when buying and selling discs were labours of love

    Record Store Day: The vinyl countdown

    For Lois Pryce, working in a record shop was a dream job - until the bean counters ruined it
    Usher, Mary J Blige and Will.i.am to give free concert as part of the Global Poverty Project

    Mary J Blige and Will.i.am to give free concert

    The concert in Washington is part of the Global Citizen project, which aims to encourage young people to donate to charity
    10 best tote bags

    Accessorise with a stylish shopper this spring: 10 best tote bags

    We find carriers with room for all your essentials (and a bit more)
    Paul Scholes column: I hear Manchester City are closing on Pep Guardiola for next summer – but I'd also love to see Jürgen Klopp managing in England

    Paul Scholes column

    I hear Manchester City are closing on Pep Guardiola for next summer – but I'd also love to see Jürgen Klopp managing in England
    Jessica Ennis-Hill: 'I just want to give it my best shot'

    Jessica Ennis-Hill: 'I just want to give it my best shot'

    The heptathlete has gone from the toast of the nation to being a sleep-deprived mum - but she’s ready to compete again. She just doesn't know how well she'll do...